Dr. Uberti on Transplant in Myelodysplastic Syndrome

Joseph Uberti, MD, PhD
Published: Tuesday, Sep 25, 2018



Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Transplant remains the only curative option for patients with MDS, but it is often underutilized by referring physicians, notes Uberti. This can be attributed to misconceptions about age requirements and the availability of donors. Older patients are often eligible for transplant and new donor match programs allow physicians to find donors for almost every patient who is eligible for transplant.

Older MDS patients tend to have comorbidities, but Uberti notes that physicians can still get these patients through a transplant. Data have shown that following transplant, 50% to 60% of patients are alive at 6 years without evidence of disease. There is a very high cure rate compared to the alternative, explains Uberti. Now, related donor transplants, unrelated donor transplants, and haploidentical transplants can be used with very similar outcomes, adds Uberti.
SELECTED
LANGUAGE


Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Transplant remains the only curative option for patients with MDS, but it is often underutilized by referring physicians, notes Uberti. This can be attributed to misconceptions about age requirements and the availability of donors. Older patients are often eligible for transplant and new donor match programs allow physicians to find donors for almost every patient who is eligible for transplant.

Older MDS patients tend to have comorbidities, but Uberti notes that physicians can still get these patients through a transplant. Data have shown that following transplant, 50% to 60% of patients are alive at 6 years without evidence of disease. There is a very high cure rate compared to the alternative, explains Uberti. Now, related donor transplants, unrelated donor transplants, and haploidentical transplants can be used with very similar outcomes, adds Uberti.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x